Listing 3 - Actual negotiations

Indication:

Febrile neutropenia in non-myeloid malignancies

Indication:

Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy

Indication:

Leptin deficiency in lipodystrophy

Indication:

Alagille syndrome

Indication:

Adjunct to standard of care therapy for the treatment of chronic heart failure in adults

Indication:

Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, and who are candidates for autologous hematopoietic stem cell transplant (HSCT)

Indication:

Seasonal allergic rhinitis

Indication:

In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Indication:

In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy

Indication:

Bardet-Biedl syndrome